Administering chemo ups income for non-salaried oncologists

Administering chemo ups income for non-salaried oncologists
Non-salaried oncologists report the potential for increased salaries with the administration of chemotherapy or growth factors for lung or colorectal cancer patients, according to a study published online Dec. 26 in the Journal of Clinical Oncology.

(HealthDay)—Non-salaried oncologists report the potential for increased salaries with the administration of chemotherapy or growth factors for lung or colorectal cancer patients, according to a study published online Dec. 26 in the Journal of Clinical Oncology.

Jennifer L. Malin, M.D., Ph.D., from the University of California at Los Angeles, and colleagues surveyed 480 U.S. oncologists involved in the care of a population-based cohort of patients with lung or colorectal cancer. The authors sought to measure the effects of prescribing chemotherapy or or making referrals to other cancer specialists, hospice, or on medical oncologists' income.

According to the researchers, most oncologists reported that their incomes would be unaffected. But, physicians in fee-for-service practice and those paid a salary with productivity incentives were significantly more likely to report that their income would increase from administering chemotherapy (odds ratios, 7.05 and 7.52, respectively) or administering growth factors (odds ratios, 5.60 and 6.03, respectively), compared with salaried oncologists.

"A substantial proportion of oncologists who are not paid a fixed salary report that their incomes increase when they administer chemotherapy and growth factors," the authors write.

One author disclosed to the pharmaceutical and health insurance industries.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Few physicians refer patients to cancer clinical trials

Feb 12, 2011

A small proportion of adult cancer patients participate in clinical trials in part due to a low level of physician referrals, according to an online study published Feb. 11 in The Journal of the National Cancer Institute.

Financial hardship common among colon cancer patients

Mar 13, 2012

(HealthDay) -- Nearly 40 percent of patients undergoing adjuvant chemotherapy for stage III colon cancer experience financial hardship, even if they have health insurance coverage, according to research published ...

Recommended for you

The fine line between breast cancer and normal tissues

11 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

12 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

14 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

16 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments